Abstract: A pipe coating material removal apparatus, comprising a support frame, a subframe, and one or more coating material removal members. The subframe is supported by the support frame and is configured to rotate relative to the support frame at least partially around a subframe rotation axis. The subframe rotation axis is configured to be substantially coaxial with a longitudinal axis of a pipe to which the apparatus may be applied in use. The, or each, coating material removal member is rotatably mounted to the subframe to remove part of an exterior coating of a pipe. The apparatus is configured such that the one or more coating material removal members enable the removal of pipe coating material at orientations substantially parallel to, and inclined with respect to, the longitudinal axis of the pipe.

Abstract: Agents, compositions, methods and kits useful for the treatment and diagnosis of Staphylococcal intramammary infection are disclosed. The agents, compositions, methods and kits are derived from genes expressed during Staphylococcal intramammary infection, and more particularly genes SACOL0442, based on the gene nomenclature from the Staphylococcus aureus COL (SACOL) genome.

Abstract: Agents, compositions, methods and kits useful for the treatment and diagnosis of Staphylococcal intramammary infection are disclosed. The agents, compositions, methods and kits are derived from genes expressed during Staphylococcal intramammary infection, and more particularly genes SACOL0029, based on the gene nomenclature from the Staphylococcus aureus COL (SACOL) genome.

Abstract: Agents, compositions, methods and kits useful for the treatment and diagnosis of Staphylococcal intramammary infection are disclosed. The agents, compositions, methods and kits are derived from genes expressed during Staphylococcal intramammary infection, and more particularly genes SACOL0442, based on the gene nomenclature from the Staphylococcus aureus COL (SACOL) genome.

Abstract: Agents, compositions, methods and kits useful for the treatment and diagnosis of Staphylococcal intramammary infection are disclosed. The agents, compositions, methods and kits are derived from genes expressed during Staphylococcal intramammary infection, and more particularly genes SACOL0029, SACOL0264, SACOL0442, SACOL0718, SACOL0720, SACOL1353, SACOL1416, SACOL1611, SACOL1944, SACOL2144, SACOL2365 or SACOL2599, based on the gene nomenclature from the Staphylococcus aureus COL (SACOL) genome.

Abstract: Agents, compositions, methods and kits useful for the treatment and diagnosis of Staphylococcal intramammary infection are disclosed. The agents, compositions, methods and kits are derived from genes expressed during Staphylococcal intramammary infection, and more particularly genes SACOL0029, SACOL0264, SACOL0442, SACOL0718, SACOL0720, SACOL1353, SACOL1416, SACOL1611, SACOL1944, SACOL2144, SACOL2365 or SACOL2599, based on the gene nomenclature from the Staphylococcus aureus COL (SACOL) genome.

Abstract: Agents, compositions, methods and kits useful for the treatment and diagnosis of Staphylococcal intramammary infection are disclosed. The agents, compositions, methods and kits are derived from genes expressed during Staphylococcal intramammary infection, and more particularly genes SACOL0029, SACOL0264, SACOL0442, SACOL0718, SACOL0720, SACOL1353, SACOL1416, SACOL1611, SACOL1944, SACOL2144, SACOL2365 or SACOL2599, based on the gene nomenclature from the Staphylococcus aureus COL (SACOL) genome.

Abstract: Agents, compositions, methods and kits useful for the treatment and diagnosis of Staphylococcal intramammary infection are disclosed. The agents, compositions, methods and kits are derived from genes expressed during Staphylococcal intramammary infection, and more particularly genes SACOL0029, SACOL0264, SACOL0442, SACOL0718, SACOL0720, SACOL1353, SACOL1416, SACOL1611, SACOL1944, SACOL2144, SACOL2365 or SACOL2599, based on the gene nomenclature from the Staphylococcus aureus COL (SACOL) genome.

Abstract: Agents, compositions, methods and kits useful for the treatment and diagnosis of Staphylococcal intramammary infection are disclosed. The agents, compositions, methods and kits are derived from genes expressed during Staphylococcal intramammary infection, and more particularly genes SACOL0029, SACOL0264, SACOL0442, SACOL0718, SACOL0720, SACOL1353, SACOL1416, SACOL1611, SACOL1944, SACOL2144, SACOL2365 or SACOL2599, based on the gene nomenclature from the Staphylococcus aureus COL (SACOL) genome.

Abstract: Agents, compositions, methods and kits useful for the treatment and diagnosis of Staphylococcal intramammary infection are disclosed. The agents, compositions, methods and kits are derived from genes expressed during Staphylococcal intramammary infection, and more particularly genes SACOL0029, SACOL0264, SACOL0442, SACOL0718, SACOL0720, SACOL1353, SACOL1416, SACOL1611, SACOL1944, SACOL2144, SACOL2365 or SACOL2599, based on the gene nomenclature from the Staphylococcus aureus COL (SACOL) genome.

Abstract: Blends of a natural wax, such as sunflower wax and glyceride materials, substantially being triglycerides and having an N20>20 display excellent properties when applied in barrier layers for compound food products.

Abstract: The invention concerns blends of fats A, B and C in the ranges:5-30% of fat A;>60% of fat B;5-20% of fat C,whereinfat A=fat having a C.sub.SAFA : C.sub.UNSAT ratio=0.5-1.3;fat B=fat having >65 wt. % of SUS;fat C=butterfat or a fraction therof.

Abstract: The presence of a specific (H.sub.2 M+HM.sub.2)-fat, either in the filling or in the coating of encapsulated fillings, results in the retardation of bloom of the chocolate composition. Therefore, the invention is concerned with encapsulated fillings, wherein the coatings display a defined (H.sub.2 M+HM.sub.2)-content. A process of preparing these encapsulated products is also included. Encapsulated products are, e.g., chocolates, pralines, biscuits, cookies, toffees, fried snacks or cakes.

Abstract: Incorporation of at least 0.5 wt. % of a hardstock rich in (H.sub.2 M+HM.sub.2)-fat into chocolate compositions results in chocolates that display improved bloom characteristics. H=saturated fatty acid with .gtoreq.C.sub.16 ; M=saturated fatty acid with C.sub.8 -C.sub.14, in particular C.sub.12 -C.sub.14.

Abstract: Blends of mid-fractions and olein fractions of the wet-fractionation of hardened soybean oil and optionally hardened palm oil olein and/or hardened cottonseed oil containing fat mixtures show improved Rancimat Induction Period (RIP) values.

Abstract: Compositions, suitable for chocolate filling, comprising a water in hard fat emulsion, wherein the particle size of the dispersed water phase is at most 50 .mu.m, are obtained by a process in which a melt of the hard fat is dispersed in an aqueous phase, after which a phase inversion is effected and the water in hard fat emulsion is obtained.

Abstract: Purified polyhedral virus particles capable of stimulating the production of interferon in animals are obtained from the fungal cells of the mold Aspergillus foetidus or Aspergillus niger or from the nutrient medium in which or on which said molds have been grown.

Abstract: Virus particles capable of stimulating the production of interferon are isolated from fungal cells of the mould Aspergillus foetidus or Aspergillus niger or from the nutrient medium in which or on which Aspergillus foetidus or Aspergillus niger mould has been grown. Double-stranded RNA material can be isolated from the virus particles extracted from Aspergillus foetidus or Aspergillus niger and said RNA material is capable of stimulating production of interferon. Pharmaceutical compositions comprising said particles or said RNA material in combination with pharmaceutically acceptable carriers and excipients are also provided.